GUARDION HEALTH (GHSI)
(Delayed Data from NSDQ)
$9.85 USD
+0.11 (1.08%)
Updated Jul 25, 2024 02:08 PM ET
After-Market: $9.71 -0.14 (-1.37%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GHSI 9.85 +0.11(1.08%)
Will GHSI be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GHSI based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for GHSI
Guardion Health Sciences Announces Completion of Sale of its Viactiv® Brand and Business to Doctor’s Best Inc. and Stockholder Approval of Plan of Liquidation and Dissolution
Guardion Health Sciences Announces Approval by Stockholders of Proposed Sale of Viactiv Business
Tandem Diabetes Care, Guardion Health, GT Biopharma among healthcare movers
Guardion Health Sciences Announces its Largest Stockholder Has Voted in Favor of Proposals to Sell the Viactiv Business and the Liquidation Plan at the Company’s Special Meeting of Stockholders to be held on May 23, 2024
Guardion Health: Largest stockholder votes in favor of Special Meeting proposals